

Metabolic Insights and Reproductive Health Challenges: High-Protein Hypocaloric Diets in PCOS Management [Letter]

Weilan Liu, Luyang Su, Shixia Zhao

Physical Examination Center, Hebei General Hospital, Shijiazhuang, Hebei, 050011, People's Republic of China

Correspondence: Weilan Liu, Email hbgh_liuweilan@163.com

Dear editor

Wang et al's randomized trial¹ comparing high-protein hypocaloric diets (HPD) with conventional restricted diets (CRD) in overweight/obese PCOS women offers critical metabolic insights but underscores unresolved reproductive health challenges. While HPD's superior preservation of fat-free mass (FFM) aligns with its anabolic potential via mTORC1 pathway activation, the equivalent reductions in HOMA-IR and testosterone between groups suggest macronutrient modulation alone may insufficiently address androgen excess or ovarian dysfunction.² Future longitudinal studies must track ovulatory frequency and serum anti-Müllerian hormone (AMH) levels to determine whether sustained FFM retention translates to restored reproductive axis function—an outcome absent in current short-term trials.

The reliance on whey protein isolates (50% of HPD intake) introduces practical limitations. Whole-food alternatives like legumes or soy not only provide equivalent protein quality but also deliver phytoestrogens and fiber, which may modulate gut dysbiosis, a contributor to PCOS-related inflammation.³ Moreover, the study's exclusion of non-obese PCOS phenotypes overlooks 30–50% of cases characterized by metabolic dysfunction despite normal BMI. Stratified analyses by waist-to-hip ratio or fasting insulin could identify subgroups where HPD exerts disproportionate benefits, particularly given evidence that lean PCOS patients exhibit unique adipokine profiles and insulin signaling defects.

Critically, the absence of structured exercise protocols represents a missed opportunity. Resistance training synergizes with dietary protein to augment FFM synthesis and insulin receptor substrate-1 (IRS-1) phosphorylation. Future trials should incorporate supervised strength training (3x/week) to test whether HPD's metabolic advantages are amplified by concurrent myofibrillar hypertrophy.⁴ Additionally, patient-reported outcomes—such as dietary satisfaction and disordered eating patterns (Eating Attitudes Test)—require quantification, as PCOS patients frequently exhibit binge-eating behaviors that undermine adherence to restrictive diets.

Mechanistic gaps persist in understanding HPD's endocrine effects. While reduced adiposity may lower aromatase activity, the parallel decline in testosterone observed in both groups implies weight loss itself, not protein composition—drives androgen reduction.⁵ To dissect dietary-specific impacts, future studies should integrate hyperinsulinemic-euglycemic clamps to isolate insulin sensitivity changes and liquid chromatography-mass spectrometry to profile steroid hormone metabolites.

Suggestions

To advance translation, we advocate for pragmatic randomized controlled trials (RCTs) co-designed by gynecologists, endocrinologists, and nutrition scientists. These should (1) track reproductive endpoints (eg, spontaneous ovulation, live birth rates), not just metabolic surrogates; (2) compare HPD against CRD combined with first-line pharmacological agents (eg, metformin, GLP-1 agonists); and (3) incorporate biomarker panels (eg, adiponectin, inflammatory cytokines) to elucidate mechanisms linking protein intake to ovarian function. Until such evidence emerges, clinicians should

emphasize HPD as a complementary strategy within multimodal PCOS management—valuable for body composition but not yet proven superior for core reproductive outcomes.

Data Sharing Statement

Data sharing is not applicable to this article as no data were created or analysed in this study.

Author Contributions

WL: Conceptualization, Writing – original draft, Writing – review and editing. LS: Writing – review and editing. SZ: Writing – review and editing. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

There is no funding to report.

Disclosure

The authors declare no conflicts of interest in this communication.

References

1. Wang F, Wei W, Liu PJ. Evaluation of effects of a high-protein hypocaloric diet on body composition and cardio-metabolic factors in women with polycystic ovary syndrome and overweight or obesity. *Diabetes Metab Syndr Obes.* 2025;18:931–939. doi:10.2147/DMSO.S501972
2. de Luis DA, Izaola O, Primo D, Aller R. Different effects of high-protein/low-carbohydrate versus standard hypocaloric diet on insulin resistance and lipid profile: role of rs16147 variant of neuropeptide Y. *Diabet Res Clin Pract.* 2019;156:107825. doi:10.1016/j.diabres.2019.107825
3. Chansa O, Shantavasinkul PC, Monsuwan W, Sirivarasai J. Association between gut microbiota profiles, dietary intake, and inflammatory markers in overweight and obese women. *Foods.* 2024;13(16):2592. doi:10.3390/foods13162592
4. Ioannidou P, Dóro Z, Schalla J, Wätjen W, Diel P, Isenmann E. Analysis of combinatory effects of free weight resistance training and a high-protein diet on body composition and strength capacity in postmenopausal women - A 12-week randomized controlled trial. *J Nutr Health Aging.* 2024;28(10):100349. Epub 2024 Sep 3. PMID: 39232439. doi:10.1016/j.jnha.2024.100349
5. Yap YW, Rusu PM, Chan AY, et al. Restriction of essential amino acids dictates the systemic metabolic response to dietary protein dilution. *Nat Commun.* 2020;11(1):2894. doi:10.1038/s41467-020-16568-z

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Diabetes, Metabolic Syndrome and Obesity 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Diabetes, Metabolic Syndrome and Obesity editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Diabetes, Metabolic Syndrome and Obesity

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal>

Dovepress
Taylor & Francis Group